Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

NCT06999408 | Active Not Recruiting FDA Device

• 1 other identifier: REC-2025-DERM-001-IIT
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determine whether this combination approach offers synergistic benefits for individuals with hair thinning. Exosomes are tiny particles that come from stem cells and contain growth factors and other nutrients. They are being studied for their potential to help regenerate skin and hair. TargetCool™ is an FDA-cleared device that uses precision cooling to reduce inflammation and improve comfort. Microneedling is a common, minimally invasive procedure that uses small needles to stimulate the skin and help absorb topical products more effectively. The study will include healthy men (ages 18 to 70) and women (ages approximately 45 to 70) who are not of childbearing potential. A total of 9 to 15 participants will be randomly placed into one of three groups: Group 1: Exosomes with TargetCool™ Group 2: Microneedling followed by exosomes and TargetCool™ Group 3: Microneedling followed by exosomes only Participants will receive four treatments over 9 weeks. Each visit may include microneedling, TargetCool™ treatment, and exosome application depending on group assignment. A small tattoo will be placed on the scalp to help capture consistent photographs, and a special imaging system (Canfield HairMetrix®) will be used to measure hair changes. Participants will return for follow-up visits at 3 and 6 months after the final treatment. The results will help determine whether this combination of cosmetic treatments is safe and beneficial for people experiencing hair thinning.

Conditions

Hair Diseases; Alopecia; Hair Thinning

Keywords

Exosomes; TargetCool; Hair thinning; mirconeedling

Outcome Measures

Primary Outcomes (4)

• Change in Terminal Hair Counts

  Terminal hair is defined as coarse hair, short or long, found on the scalp with minimum cross-sectional diameter of 40 micrometers. This is calculated by the Canfield HairMetrix System.

  32 weeks (8 months)

• Change in Vellus Hair Counts

  Vellus hair is defined as fine, short hairs found on the scalp with maximum cross-sectional diameter of 40 micrometers. This is calculated by the Canfield HairMetrix System.

  32 weeks (8 months)

• Change in Total Hair Counts

  Total hairs equals the sum of Terminal and Vellus hairs in the target area. This is calculated by the Canfield HairMetrix System.

  32 weeks (8 months)

• Change in average hair width

  This is the average hair width calculated in micrometers by the Canfield HairMetrix System.

  32 weeks (8 months)

Secondary Outcomes (3)

• Change in Investigator Hair Growth Global Improvement Scale

  32 weeks (8 months)

• Change in Subject Hair Self-Assessment Questionnaire scores

  32 weeks (8 months)

• Change in Hair Treatment Subject Satisfaction Questionnaire scores

  32 weeks (8 months)

Other Outcomes (1)

• Frequency of both local and systemic Adverse Events

  32 weeks (8 months)

Study Arms (3)

TargetCool with Benev exosome Boost

ACTIVE COMPARATOR

Device: Scalp tattoo; Device: Canfield HairMetrix®; Device: TargetCool

Microneedling followed by TargetCool Boosting with Benev exosome

ACTIVE COMPARATOR

Device: Scalp tattoo; Device: Canfield HairMetrix®; Device: TargetCool; Device: Microneedle-facilitated lidocaine application

Microneedling to depth of 0.5mm followed by Benev exosome topical

ACTIVE COMPARATOR

Device: Scalp tattoo; Device: Canfield HairMetrix®; Device: Microneedle-facilitated lidocaine application

Interventions

Scalp tattoo DEVICE

A micropigmentation scalp tattoo will be applied at baseline to mark consistent photographic sites.

Microneedling followed by TargetCool Boosting with Benev exosome; Microneedling to depth of 0.5mm followed by Benev exosome topical; TargetCool with Benev exosome Boost

Canfield HairMetrix® DEVICE

Canfield HairMetrix® imaging will be utilized to capture global and trichoscopic hair measurements.

Microneedling followed by TargetCool Boosting with Benev exosome; Microneedling to depth of 0.5mm followed by Benev exosome topical; TargetCool with Benev exosome Boost

TargetCool DEVICE

Boosting will be used to apply exosomes

Microneedling followed by TargetCool Boosting with Benev exosome; TargetCool with Benev exosome Boost

Microneedle-facilitated lidocaine application DEVICE

Microneedling will be performed to a depth of 0.5 mm.

Microneedling followed by TargetCool Boosting with Benev exosome; Microneedling to depth of 0.5mm followed by Benev exosome topical

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy males between 18-70 years of age and females not of child-bearing age 45-70 years of age of all Fitzpatrick Skin Types.
• Subjects must be willing to provide verbal understanding and sign an Informed Consent Form, HIPAA Form and Photography Release Form approved by the Institutional Review Board.
• Subjects must be in general good health, as determined by the Investigator.
• Subjects with hair thinning as determined on initial study assessment by the Investigator.
• Patients are not on medical treatment or have been on stable treatment for \>12 months (eg. minoxidil, finasteride, dutasteride, PRP, LLLT)
• Subjects willing to not substantially change their current diet, medications, or exercise routines for the duration of the study. If a subject receives physician guidance during the study to change diet, medications, or exercise routine, the subject will need to notify the clinic as soon as possible.
• Subjects willing to have Canfield digital photography of the entire head/hair region for overall evaluation of general hair growth and quality by the Investigator.
• Subjects willing to have TargetCool boosting or microneedling of the scalp region with or followers by application of exosomes.
• Subjects must be willing and able to complete and understand the rating questionnaires.
• Subjects must be willing and able to attend all study visits and comply with the post procedure and lifestyle instructions

You may not qualify if:

• Subjects who are of child-bearing age, pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.
• Subjects who have had a hair transplant.
• Subjects who have recently (within the last 3 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (3 months or longer) in order to be eligible for the study.
• Subjects who started any new hair loss treatment in the last 12 months.
• Subjects who have used prescription drugs known to affect the hair growth cycle within the last 3 months (e.g., hormone-based birth control for less than 12 months, cyproterone acetate, aldactone/spironolactone or any 5-alpha-reductase inhibitor).
• Subjects who have regularly used anti-androgenic therapies (i.e. spironolactone, flutamide, cyproterone acetate, progesterone and/or bicalutamide) or undergone any other hair or scalp treatments within the last 12 months.
• Subjects suffering from other hair loss disorders, such as alopecia areata, scarring alopecia, and telogen effluvium as determined during initial study assessment and physical exam by the Investigator.
• Subjects with self-reported uncontrolled diseases (i.e. diabetes, hypertension, hyperthyroidism, hypothyroidism, etc.). Whether medical conditions are under control with or without treatment will be assessed on an individual basis by the Investigator based on her medical and clinical expertise.

Sponsors & Collaborators

• Recens Medical, Inc.: lead
• Benev Company, Inc.: collaborator

Study Sites (1)

Marc Avram MD

New York, New York, 10021, United States

Location

Related Publications (6)

• Ha DH, Kim SD, Lee J, Kwon HH, Park GH, Yang SH, Jung JY, Lee JH, Park SR, Youn J, Lee SH, Kim JE, Lim J, Lee HK, Cho BS, Yi YW. Toxicological evaluation of exosomes derived from human adipose tissue-derived mesenchymal stem/stromal cells. Regul Toxicol Pharmacol. 2020 Aug;115:104686. doi: 10.1016/j.yrtph.2020.104686. Epub 2020 May 22.

  PMID: 32450131 BACKGROUND

• Ersan M, Ozer E, Akin O, Tasli PN, Sahin F. Effectiveness of Exosome Treatment in Androgenetic Alopecia: Outcomes of a Prospective Study. Aesthetic Plast Surg. 2024 Nov;48(21):4262-4271. doi: 10.1007/s00266-024-04332-3. Epub 2024 Aug 22.

  PMID: 39174804 BACKGROUND

• Zhou Y, Seo J, Tu S, Nanmo A, Kageyama T, Fukuda J. Exosomes for hair growth and regeneration. J Biosci Bioeng. 2024 Jan;137(1):1-8. doi: 10.1016/j.jbiosc.2023.11.001. Epub 2023 Nov 23.

  PMID: 37996318 BACKGROUND

• Kost Y, Muskat A, Mhaimeed N, Nazarian RS, Kobets K. Exosome therapy in hair regeneration: A literature review of the evidence, challenges, and future opportunities. J Cosmet Dermatol. 2022 Aug;21(8):3226-3231. doi: 10.1111/jocd.15008. Epub 2022 Jun 2.

  PMID: 35441799 BACKGROUND

• Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: Preliminary evidence, safety, and future directions. J Cosmet Dermatol. 2023 Sep;22(9):2424-2433. doi: 10.1111/jocd.15869. Epub 2023 Jun 28.

  PMID: 37381168 BACKGROUND

• Queen D, Avram MR. Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatol Surg. 2025 Apr 1;51(4):409-415. doi: 10.1097/DSS.0000000000004480. Epub 2024 Oct 24.

  PMID: 39447204 BACKGROUND

Related Links

• TargetCool
• Exosome Regenerative Complex+

MeSH Terms

Conditions

Hair Diseases; Alopecia

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Hypotrichosis; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Marc Avram, MD

  PRINCIPAL INVESTIGATOR

• Dawn Queen, MD

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2025
• First Posted: May 31, 2025
• Study Start: September 16, 2025
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: March 9, 2026

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: Beginning 6 months after publication and available for up to 2 years.
• Access Criteria: Requests must include a brief proposal outlining study aims and methodology. The study team will review each request for scientific merit. Data will be shared via secure, password-protected transfer. Researchers may request access by contacting michele@dravram.com.

Locations

US (1)